Kite Enters Allogenic Cell Therapy Collab with Startup Appia Bio for $875 Million

Gilead Sciences’ Kite Pharma has entered into a collaboration and licensing agreement with biotech startup Appia Bio, which will focus on the joint research and development of allogeneic cell therapies for cancer. The collaboration agreement comes six weeks after Kite Pharma signed a $2.3 billion strategic partnership deal with Shoreline Biosciences for the development of off-the-shelf cell therapies.